anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a barrier membrane to which a peptide, which binds to collagen and which is capable of regenerating bone tissue, is bound. More particularly, the present invention relates to a collagen barrier membrane in which a fusion peptide consisting of a collagen-bound peptide and a functional bone-tissue-regenerating peptide is fixed to the surface of collagen. According to the present invention, the surface-active collagen barrier membrane, in which a fusion peptide is coupled to the surface of collagen, can stably bind to the body due to increased local retention, and promote the transport, proliferation, and differentiation of cells, to thereby ultimately maximize bone-tissue-regenerating capacity when implanted in the body. Therefore, the barrier membrane of the present invention is useful in the development of guided bone-regeneration technology. In addition, a fusion peptide can be applied to implants made of collagen having other shapes, and a collagen-bound peptide, which constitutes the fusion peptide, can be bound to and synthesized with a peptide having effects in regenerating other tissue, and therefore can be useful in tissue-regenerating biomaterials for other purposes, e.g. for regenerating skin.
Chlorogenic acid, i.e. 1, 3, 4, 5-tetrahydroxycyclohexanecarboxylic acid-(3, 4-dihydroxycinnamic acid ester), exists in a plurality of plants, and also, high purity chlorogenic acid can be prepared through synthesis. Chlorogenic acid has a lot of biological activity, such as antibacterium, antivirus, antioxidation, antitumor and the like. However, there exists no report and research on oral preparations prepared by high purity chlorogenic acid and application of the preparations in clinics. In the invention, high purity chlorogenic acid is extracted from plants or obtained through synthesis, and is then added with a proper amount of accessories, thus obtaining oral preparations like tablets, capsules, granules, oral solutions, etc. The preparations provided in the invention can be applied in clinics for treating cardio-cerebrovascular diseases, infections, hepatitis B, tumors and other diseases, and also can be used in health care medicines for heat clearing and detoxifying, face nursing and skin moistening, as well as hangover relieving, etc.
Apply soluble hyaluronic acid microneedle eye mask to the periorbital area after normal facial cleansing and skin care every night for 20 days. Press and hold for 3 minutes, and then remove it after 1 h. Every 2 days for the next 20 days, and every 3 days for the last 21 days. Follow-up time: every 20 days during the treatment period, and follow-up visits in the 2nd, 4th, 8th and 12th weeks after the treatment.
The control group receives 0.9% NaCl physiological saline. Caregivers will spray the children twice daily (morning and afternoon), administering 2 sprays in each nostril and 2 sprays in the throat each time (totally 6 sprays each time) for a continuous period of 4 weeks, starting from the time of study participation.
A system for the delivery of contrast agents such as manganese (MR-active Mn2+ or other manganese isotopes) into extravascular body compartments in living subjects (mammals, amphibians, fish etc.) is described. The compound consists of alginate, manganese ions and other stabilizing ions (Ba2+, Ca2+ etc.) in a gel, formed by mixing of alginate and solutions of the ions mentioned above. The primary alginate used in production of the compound can be adjusted in structure (M- and G-block content and sequence), molecular weight and concentration. In addition, the salt solution and concentration can be varied in order to produce alginate gels of variable manganese amount (dose) and local manganese release rate (dose-rate). When injected or implanted into extravascular body compartments manganese ions will be released from the gel by ion exchange with body fluids and passive diffusion. Once released the manganese ions shortens the longitudinal MR relaxation time of water molecules in their vicinity amounting to positive image contrast in T1-weighted MR images. Furthermore, the compound may also act as slow release agent for positron emission tomography scanning, provided the manganese-isotope is emitting positrons (m52mMn).
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to oncology, pulmonology, and can be used to improve functional operability in patients with lung cancer diagnosed against the background of chronic obstructive pulmonary disease (COPD) III-VI degree by eliminating dysfunction of the respiratory and skeletal muscles and improving breathing mechanics. To do this, at the outpatient stage, two weeks before surgical treatment, a set of physical training is prescribed, including cycles of breathing, strength and aerobic exercises. The complex begins with a cycle of breathing exercises. The cycle of strength training is performed using a stick or elastic band with the inclusion of exercises for the upper and lower muscle groups. The complex is completed by performing a cycle of aerobic training, including walking, exercise bike or swimming at the patient's choice. The set of exercises is selected individually depending on the physical status of the patient and performed daily for two weeks.EFFECT: method provides reduction of treatment time, as well as improvement of indicators of functional operability in cancer patients.1 cl, 1 ex
Placebo is an isocaloric product containing maltodextrins instead of amino acids (Acquilani et al., 2011). The placebo will be administered orally 4.5 g twice daily.
Coconut oil (Parachute Brand) is a marketed product that is routinely used for daily massage after birth for infants in India. An amount of 5 mg/Kg body weight will be applied twice daily by the health care provider from enrollment until discharge, or until day of life 28, whichever occurs first.
FIELD: chemistry. ^ SUBSTANCE: invention relates to novel sulphonamidethiazole pyrimidine derivatives of formula (I) ^ , which are glucokinase activators or to their enantiomers, mixture of enantiomers or pharmaceutically acceptable salts. The invention also relates to a pharmaceutical composition based on the novel compounds, use of the compounds to prepare a medicinal agent and to a method of activating glucokinase. In formula (I) R1 denotes (C1-C10)alkoxy, R2 denotes (C3-C6)cycloalkyl, R3 denotes hydrogen, and values of substitutes R4 and R5 are given in the formula of invention. ^ EFFECT: more effective use of the compounds. ^ 33 cl, 166 ex
The schedule for vaccination will be Days 1, 4, 8, 15, and 22 (delays of up to 96 hours are allowed for each dose based on the adverse events experienced). Additional vaccinations will be given on Days 50 and 78 (+/- 2 weeks). The first vaccine dose may be administered following confirmation of disease-free status and within 90 days following date of repeat imaging. All study injections will be given subcutaneously and co-administered with poly-ICLC by a trained healthcare provider.
The use of stents has become common practice in the percutaneous treatment of coronary artery disease. Restenosis affected 20-40% of de novo coronary lesions treated with bare metal stents. Drug-eluting stents (DES) have emerged as the most effective strategy for the prevention of restenosis. The first available DES were the Sirolimus-eluting Cypher and the Paclitaxel-eluting Taxus stent. Although their mid-term efficacy has been well-established, there is an ongoing debate on the potential of an increased incidence of late stent thrombosis, as well as of delayed onset of restenosis or catch-up phenomenon with DES. Recent evidence demonstrates that there might be differences between various DES in terms of safety and efficacy. The differences might be related to the drug, polymer or stent design. Everolimus (SDZ-RAD) and zotarolimus (ABT-578) are new antiproliferative agents that share some common structural and biological properties with sirolimus ("limus-group"). Both drugs bind to the intracellular sirolimus receptor, FK 506-binding protein 12 (FKBP 12). The drug-FKBP12 complex inhibits cell cycle progression via inactivation of the mammalian target of Rapamycin (mTOR) thereby regulating vascular smooth muscle cell migration and proliferation. Preclinical studies showed improved endothelialization and limited chronic inflammation of the everolimus-eluting stent compared with previous drug-eluting stents. Moreover, first randomized clinical trials of everolimus-eluting stents have shown promising results regarding safety, feasibility and efficacy in the suppression of neointimal proliferation. Safety and efficacy of the zotarolimus-eluting Endeavor stent have been investigated in the Endeavor clinical program. In the Endeavor III and IV trials, the Endeavour stent proved inferior to the Cypher and Taxus stents regarding angiographic endpoints. However, rates of target vessel failure were similar in both groups. The Endeavor RESOLUTE stent platform uses a new polymer with potential improvements of drug release compared to the Endeavor stent. The RESOLUTE clinical trial is the first-in man, observational, uncontrolled, non-randomized study evaluating the Endeavor Resolute drug-eluting stent with the new polymer. The trial enrolled a total of 130 patients with native coronary artery lesions. There are no data available comparing the zotarolimus-eluting Endeavor Resolute stent with the everolimus-eluting Xience V stent. Thus the aim of this prospective, randomized study is to compare the efficacy and safety of these two "new generation" drug-eluting stent platforms in a real world population.
The mechanism of the antihypertensive effect of thiazides is unknown. DIURIL (chlorothiazide) does not usually affect normal blood pressure. 

DIURIL (chlorothiazide) affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are approximately equal in their diuretic efficacy. 

DIURIL (chlorothiazide) increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. 

After oral use diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours. Following intravenous use of Sodium DIURIL, onset of the diuretic action occurs in 15 minutes and the maximal action in 30 minutes.
A tetrahydroindolone derivative or analogue comprises a 9-atom bicyclic moiety, moiety A, linked through a linker L to a moiety B, where B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y1)-D, where Y1 can be one of a variety of substituents, including hydrogen or alkyl, and D is a moiety that enhances the pharmacological effects, promotes absorption or blood-brain barrier penetration of the derivative or analogue. The moiety A has a six-membered ring fused to a five-membered ring. The moiety A can be have one, two, or three nitrogen atoms in the five membered ring. The moiety A can be a tetrahydroindolone moiety. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biological or physiological activity. In general, a bifunctional conjugate according to the present invention has the schematic structure (1) where A is a 9-atomic bicycle moiety in which the five-membered ring has 1 to 3 nitrogen atoms, the bicyclic moiety having the structure (2).
Patients will be treated with NALIRINOX, a combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin. Treatment regimen will consist of 8 cycles of neoadjuvant NALIRINOX prior to surgery and trial duration is expected to be 24 months.
Stroke is a leading cause of death in the US and around the world but with limited treatment options. Survivors often present with long-term cognitive and neurological deficits. Stem cell-based therapy has emerged as a potential treatment for stroke. While stem cell transplantation in stroke has reached clinical trials, mostly safety outcomes have been reported with efficacy readouts warranting more studies. In an effort to optimize the stem cell regimen for stroke, here we conducted vis-a-vis comparison of different routes of transplantation, namely, intracerebral, intraarterial, and intranasal delivery of expanded human CD34 + stem cells, called ProtheraCytes, in the established stroke model of transient middle cerebral artery occlusion (MCAO) using adult Sprague-Dawley rats. After adjusting for the dose and subacute timing of cell delivery, animals were randomly assigned to receive either ProtheraCytes or vehicle. Motor and neurological assays from days 7 to 28 post-stroke revealed significant functional recovery across all 3 delivery routes of ProtheraCytes compared to vehicle-treated stroke rats. Additionally, ProtheraCytes-transplanted stroke rats displayed significantly reduced infarct size and cell loss in the peri-infarct area coupled with enhanced neurogenesis and angiogenesis compared to vehicle-treated stroke rats. These results highlight the safety and efficacy of transplanting ProtheraCytes, including via the minimally invasive intranasal route, in conferring robust and stable behavioral and histological positive outcomes in experimental stroke.
During Pandemic: The investigators will query the parent/guardian with the 2-question food insecurity validated tool during their regular appointment, either in person or on the phone/telehealth. If a positive response is given, the investigators will ask if the food insecurity began or worsened during the pandemic in the past 1 to 2 months.
Clopidogrel bisulfate is a thienopyridine class inhibitor of P2Y12 ADP platelet receptors. Chemically it is methyl (+)-(S)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)acetate sulfate (1:1). The molecular formula of clopidogrel bisulfate is C16H16ClNO2S•H2SO4 and its molecular weight is 419.9. 

The structural formula is as follows: 

Clopidogrel bisulfate, USP is a white to off-white powder. It is practically insoluble in water at neutral pH but freely soluble at pH 1. It also dissolves freely in methanol, dissolves sparingly in methylene chloride, and is practically insoluble in ethyl ether. It has a specific optical rotation of about +56°. 

Each clopidogrel tablet intended for oral administration is provided as pink-colored, biconvex, round-shaped, film-coated tablets contains 97.830 mg of clopidogrel bisulfate, which is molar equivalent to 75 mg of clopidogrel base. In addition, each tablet contains the following inactive ingredients: citric acid, colloidal silicon dioxide, corn starch, crospovidone, hydrogenated castor oil, hydroxypropyl cellulose, hypromellose, iron oxide black, iron oxide red, iron oxide yellow, lactose anhydrous, lactose monohydrate, magnesium stearate, polyethylene glycol and titanium dioxide.
The present invention provides synthetic chimeric fimbrin peptides which induce an immunogenic response in animals to non-typable  Haemophilus influenzae  and that do not require tedious purification techniques. The synthetic chimeric fimbrin peptides reduce the severity of otitis media caused by  Haemophilus influenzae . The synthetic chimeric fimbrin peptides are synthesized using commercially available peptide synthesizers. The synthetic chimeric fimbrin peptides comprises three peptide units. The first peptide unit is a subunit of the fimbrin protein. Preferably, the fimbrin subunit is comprised of the amino acids of Sequence ID No. 1 or Sequence ID No. 2. The second peptide unit is a t cell epitope, and preferably has the amino acid sequence of SEQ ID NO. 3. The third peptide unit is a linker peptide unit which joins the first and second peptide unit. The linking sequence preferably has from about 2 to about 15 amino acids, more preferably from about 2 to about 10 amino acids, most preferably from about 5 to about 6 amino acids. The synthetic chimeric fimbrin peptides are useful immunognes against NTHi and also useful as laboratory tool for detecting antibodies in sera. The invention also relates to an immunogenic composition containing the synthetic chimeric fimbrin peptides and a pharmacologically acceptable carrier.
Sleep disordered breathing (SDB) is an important paediatric problem. It is estimated that 3.2% to 12.1% of children have habitual snoring and 0.7% to 10.3% have obstructive sleep apnea syndrome (OSAS). Children OSAS is associated with a series of daytime and nighttime signs and symptoms. Nighttime symptoms include heavy snoring, restless sleep, heavy seating and enuresis, etc. Daytime symptoms include excessive daytime sleepiness and abnormal behavior such as aggressiveness and hyperactivity, etc. Untreated OSAS was reported to result in serious morbidity, such as failure to thrive, poor learning, attention deficit and hyperactivity disorder, etc.

There is an increasing concern related to sleep disordered breathing(SDB) of children by orthodontists. Since not only the tonsilar and adenoid hypertrophy is the main cause of paediatric OSA, but also craniofacial anomalies such as retrognathic mandible, narrow maxillary palatal arch and increased lower facial height can also contribute to it, orthopedic treatment such as rapid maxillary expansion (RME) and mandibular advancement device (MAD) may potentially permanently cure the children OSA. RME which is used to widen maxilla, thus increasing the nasal cavity and improving the nasal flow, has been thoroughly researched. However, only a few previous studies focused on the treatment effect of MAD for treating OSA children. These studies showed sorts of MAD such as jaw-positioning appliance, mono-block, and Herbst appliance were effective to OSA children, but it remains unclear how to choose a functional appliance, and if there is any treatment difference between removable functional appliance and fixed functional appliance for improving airway dimension.
FIELD: medicine. SUBSTANCE: invention relates to a pharmaceutical composition used for treatment and prophylaxis of acute and chronic liver sicknesses, disorders of lipid metabolism in atherosclerosis and concomitant diseases, for recovery of liver function in an intoxication. Composition has phospholipids, glycyrrhizic acid or its salts and accessory substances at total content of phospholipids and glycyrrhizic acid or its salt 2-80 wt.-% and at mass ratio of phospholipids to glycyrrhizic acid or its salt 4:1, not above. Composition is made as granulate, tablet or injection formula. It can be stored for the long time, shows high effectiveness and low toxicity. EFFECT: enhanced effectiveness, high quality and properties of composition. 12 cl, 7 dwg, 8 tbl, 9 ex
The present invention is a system and a method to classify clinical records into International Classification of Diseases (ICD) codes. The system includes a processor, and a memory communicatively coupled to the processor. The memory includes a generator (G), a feature extractor, a discriminator (D), a label encoder, and a keywords reconstructor. The generator (G) generates synthesized features corresponding to ICD code descriptions. The feature extractor extracts real latent features from clinical documents and generates real features by training a GANs. The generator (G) generates synthesized features after the GANs are trained and calibrate a binary code classifier with the real latent features generated by the feature extractor for a low-shot ICD code l. The feature extractor generates code-specific latent features conditioned on a textual description of each ICD code description by using a WGAN-GP. The discriminator (D) distinguishes between the synthesized features and the real features and determines whether the features are the real features or synthetic features. The label encoder encodes a sequence of keywords in the ICD code description into a sequence of hidden states.
Pressure overload-induced pathological cardiac hypertrophy eventually leads to heart failure (HF). Unfortunately, lack of effective targeted therapies for HF remains a challenge in clinical management. Mixed-lineage leukemia 4 (MLL4) is a member of the SET family of histone methyltransferase enzymes, which possesses histone H3 lysine 4 (H3K4)-specific methyltransferase activity. However, whether and how MLL4 regulates cardiac function is not reported in adult HF. Here we report that MLL4 is required for endoplasmic reticulum (ER) stress homeostasis of cardiomyocytes and protective against pressure overload-induced cardiac hypertrophy and HF. We observed that MLL4 is increased in the heart tissue of HF mouse model and HF patients. The cardiomyocyte-specific deletion of Mll4 (Mll4-cKO) in mice leads to aggravated ER stress and cardiac dysfunction following pressure overloading. MLL4 knockdown neonatal rat cardiomyocytes (NRCMs) also display accelerated decompensated ER stress and hypertrophy induced by phenylephrine (PE). The combined analysis of Cleavage Under Targets and Tagmentation sequencing (CUT&Tag-seq) and RNA sequencing (RNA-seq) data reveals that, silencing of Mll4 alters the chromatin landscape for H3K4me1 modification and gene expression patterns in NRCMs. Interestingly, the deficiency of MLL4 results in a marked reduction of H3K4me1 and H3K27ac occupations on Thrombospondin-4 (Thbs4) gene loci, as well as Thbs4 gene expression. Mechanistically, MLL4 acts as a transcriptional activator of Thbs4 through mono-methylation of H3K4 and further regulates THBS4-dependent ER stress response, ultimately plays a role in HF. Our study indicates that pharmacologically targeting MLL4 and ER stress might be a valid therapeutic approach to protect against cardiac hypertrophy and HF.
Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors, including enalapril maleate. This may occur at any time during treatment. In such cases enalapril maleate should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly provided (see ADVERSE REACTIONS). 

Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema (see PRECAUTIONS). 

### Intestinal Angioedema

Intestinal angioedema has been reported in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain.

Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see also INDICATIONS AND USAGE and CONTRAINDICATIONS).